Shenwei Pharmaceutical announced on May 6 on the Hong Kong Stock Exchange that the company and its subsidiaries had a turnover of 1,118 billion yuan in management accounts for the first quarter of 2024, which was 6.1% lower than in the same quarter of 2023. The turnover of injectable products decreased by 17.0% to 406 million yuan; the turnover of softgel products increased by 2.4% to 172 million yuan; the turnover of granular products increased by 37.2% to 199 million yuan; the turnover of granulated products with traditional Chinese medicine decreased by 12.9% to 283 million yuan; and the turnover of other dosage products decreased by 9.4% to 58 million yuan, respectively.
神威药业：一季度未经核数师审阅管理账目内营业额11.18亿元，同比减少6.1%
Shenwei Pharmaceutical: Revenue in the management accounts in the first quarter was 1,118 billion yuan without auditor review, a decrease of 6.1% over the previous year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.